$295.00
+0.58%Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Advisor
Compensation
$2,111,081
Chairman, Chief Executive Officer & President
Compensation
$5,275,782
Chief Technology Officer and Vice President of Global R&D - Joint Replacement
Group President of Global Quality & Operations
Compensation
$1,567,937
Group President of MedSurg & Neurotechnology
Compensation
$1,879,020
Group President of Orthopaedics
Compensation
$1,879,020
Group President of Orthopaedics & Spine
Compensation
$1,879,020
Vice President & Chief Accounting Officer
Vice President & Chief Financial Officer
Vice President of Finance & Investor Relations
Vice President, Chief Information Officer & Chief Information Security Officer
During the last 12 months, insiders have sold $11.33M worth of SYK shares, with no buying activity reported.
0
0.00
9.0K
2.69M
-2.7M
-$2.69M
0
0.00
14.9K
5.35M
-5.4M
-$5.35M
0
0.00
4.1K
1.46M
-1.5M
-$1.46M
0
0.00
4.7K
1.83M
-1.8M
-$1.83M
No buying activity
Stryker Ronda E
Director
$7.97M
Fink M Kathryn
Officer: Vp, Chief Hr Officer
$1.48M
Fletcher Robert S
Officer: Vp, Chief Legal Officer
$738K
Berry William E Jr
Officer: Vp, Chief Accounting Officer
$714K
Menon Viju
Officer: Group President
$195K
Strong bearish signal with $11.33M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SYK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 23, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 25, 2025 | May 08, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 26, 2024 | May 09, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 28, 2023 | March 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 23, 2022 | May 04, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 24, 2021 | May 05, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 24, 2020 | May 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 20, 2019 | May 01, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 21, 2018 | May 02, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 20, 2017 | May 03, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.